个人简介
David Wang is a Senior Managing Director, Asia. Most recently, Dr. Wang was a Managing Director at WI Harper Group, responsible for healthcare investment in China. Previously, he served as Head of Business Development at Siemens Medical Solutions, where he directed corporate strategy and new businesses in molecular diagnostics and diagnostic imaging. Dr. Wang was co-founder and Executive Vice President at First Genetic Trust, a personalized medicine company. During his tenure at Bristol-Myers Squibb, Dr. David Wang was Chairman of The SNP Consortium Management Committee where he was responsible for strategy and management of the consortium. The SNP Consortium is the first group of its kind formed by pharmaceutical and technology industries as well as academia and charities to support the development of personalized medicine. Dr. David Wang received his M.D. from Peking University Medical School. He earned his doctorate in Developmental Biology from California Institute of Technology.
知名人物
--
投资总监
--
投资总监
--
投资总监
热销私募股权
股权投资
投资方向
存续期限12+6月
起投金额500万
股权投资
投资方向
存续期限3+1+1年
起投金额30万
股权投资
投资方向
存续期限--
起投金额100万
股权投资
投资方向
存续期限12+6月
起投金额100万
根据《信托公司集合资金信托计划管理办法》、《私募投资基金监督管理暂行办法》之规定,只向特定投资者展示私募基金和信托资管产品信息,不构成任何投资推介建议。
阁下如有意了解合格投资者认定标准,请移步查看 《信托公司集合资金信托计划管理办法》、《私募投资基金监督管理暂行办法》相关规定。
阁下如有意了解或进行信托及私募基金投资,请注册成为中投在线用户,确认您为合格投资者身份。
高端会员专享产品 . 让业绩更高福利更多
稀缺产品
节日福利
线下体验